Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel OpGen OTC:OPGN.Q, US68373L3078

  • 0,377 29 sep 2022 22:00
  • -0,003 (-0,89%) Dagrange 0,371 - 0,394
  • 116.709 Gem. (3M) 283,3K

Curetis-Opgen 2022 / Zal het dan dit jaar wat worden ?

36 Posts
Pagina: «« 1 2 | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 27 mei 2022 11:48
    quote:

    DAGEVOS schreef op 27 mei 2022 11:06:

    Ik geloof er nog steeds in. Gisteren mooie koerssprong op het bericht dat een test 39 behandeluren kan winnen. Gezondheidszorginstellingen zullen gedwongen worden om dit soort testen te gaan gebruiken als er nog meer geldschaarste komt. Kwestie van tijd. Een RS ligt in het verschiet, maar hoeft niet perse nadelig te zijn.
    Ook de verkoop van een onderdeel aan China kan flink geld in het laatje brengen.
    Verder beetje gebruikmaken op grillige koersbewegingen. Volgens mij ligt de waarde van het aandeel rond de 30 cent.
    Reële Kaspositie/ koers. Gemiddelde aankoop 0,84ct. Nog een lange weg te gaan. Volgend jaar verwacht ik de eerste echte tekenen van groei.
    Vergeet dit rampenfonds maar gauw, want dit wordt niks meer.

    Een de volgende RS zal de koersval versnellen, want er komen dan weer miljoenen nieuwe aandelen bij.
  2. forum rang 4 Pitmans 28 mei 2022 15:59
    Volg ik. Heb ik behalve een hoop onzin nooit iets gezien van een verkoop van activiteiten aan een chinese partij.
    Wel iets van een nog steeds hangende chinese goedkeuring waar weer een afnamecontract van af hangt, maar dat is niet wat jij beschrijft.
    Als je toch wil proberen de koers op te krikken, doe dat dan met feiten en niet met iets op yahoo conversations.

    Straks ga je nog naar stocktwits verwijzen voor 'nieuws' en 'advies'
  3. forum rang 4 Pitmans 28 mei 2022 16:23
    "Once NMPA approves the products, BCB has agreed to contractual minimum purchases of 360 Unyvero systems and more than 1.5 million cartridges cumulative over an 8-year exclusivity period which at current transfer prices between the parties is expected to amount to approximately $180 million in revenue to OpGen at current exchange rates."

    ir.opgen.com/news-releases/news-relea...

    Voor de volledigheid : "announced today that it has recently received regulatory approval of the Curetis Unyvero System as an in vitro diagnostics (IVD) instrument system in China from the Chinese authorities"

    Maar : "Once we also receive NMPA approval for the Unyvero pneumonia cartridge for the Chinese market we expect a swift commercial launch in China by our partners BCB "

    Het apparaat is dus al goedgekeurd, maar de cartridges voor de tests nog niet.
  4. forum rang 10 DeZwarteRidder 28 mei 2022 17:30
    quote:

    Pitmans schreef op 28 mei 2022 16:23:

    "Once NMPA approves the products, BCB has agreed to contractual minimum purchases of 360 Unyvero systems and more than 1.5 million cartridges cumulative over an 8-year exclusivity period which at current transfer prices between the parties is expected to amount to approximately $180 million in revenue to OpGen at current exchange rates."

    ir.opgen.com/news-releases/news-relea...

    Voor de volledigheid : "announced today that it has recently received regulatory approval of the Curetis Unyvero System as an in vitro diagnostics (IVD) instrument system in China from the Chinese authorities"

    Maar : "Once we also receive NMPA approval for the Unyvero pneumonia cartridge for the Chinese market we expect a swift commercial launch in China by our partners BCB "

    Het apparaat is dus al goedgekeurd, maar de cartridges voor de tests nog niet.
    Gewoonlijk komt er niks terecht van Chinese deals.
  5. DAGEVOS 31 mei 2022 19:27
    Ik hou ze voorlopig nog vast. Het kan zo maar zijn dat hij boven de dollar noteert binnenkort. Opgn is altijd verrassend, zowel naar beneden als naar boven. Als je het geld niet direct nodig hebt dan laten staan tot bv eind van het jaar. Er komen best wel positieve berichten het komend half jaar. Is mijn verwachting.
  6. forum rang 4 Pitmans 11 augustus 2022 23:31
    H1 omzet $1,4mio. Deze CEO is duidelijk zijn jaarsalaris van $400k+ waard.

    OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update
    Thu, August 11, 2022 at 10:15 PM
    Total Q2 2022 revenues of $1.0 million with product sales a key growth driver

    First two commercial customer contracts for Acuitas AMR Gene Panel signed in June and July 2022

    Requested additional 180-day period to regain compliance with Nasdaq minimum bid price rule

    Management conference call scheduled for August 11th, 2022, at 4:30 p.m. EDT

    ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.

    Oliver Schacht, President & CEO of OpGen, commented, “We are pleased with the progress we’ve made in the first half of 2022, which includes signing two commercial contracts for our Acuitas AMR Gene Panel with two major U.S. hospitals. Additionally, we have added a fourth trial site and continued enrollment towards our 1,500th patient sample for the clinical trial for Unyvero Urinary Tract Infection (UTI) Panel. We anticipate completing the enrollment and expect final data read out in the second half of this year towards an FDA submission.”

    Dr. Schacht continued, “Overall we are tracking well against our R&D milestones and continue to progress on the commercial front with significant growth in direct product sales year over year. We look forward to continuing to update on our progress and continue the fight against antimicrobial resistance.”

    Second Quarter and First Half 2022 Financial Results of OpGen, Inc.

    Total revenue for the second quarter of 2022 was approximately $1.0 million, compared with approximately $0.8 million in the second quarter of 2021. Total revenue for the first half of 2022 was approximately $1.4 million, as compared to approximately $1.6 million for the first half of 2021.

    Operating expenses for the second quarter of 2022 were approximately $6.2 million, compared with approximately $7.0 million in the second quarter of 2021. Operating expenses for the first half of 2022 were approximately $12.6 million, compared with approximately $14.0 million in the first half of 2021.

    The net loss available to common stockholders for the second quarter of 2022 was approximately $5.8 million, or $0.13 per share, compared with approximately $7.1 million, or $0.19 per share, in the second quarter of 2021. The net loss available to common stockholders for the first half of 2022 was approximately $12.6 million, or $0.27 per share, compared with approximately $21.9 million, or $0.65 per share, in the first half of 2021.

    Cash and cash equivalents were approximately $16.6 million as of June 30, 2022, compared with $36.1 million as of December 31, 2021.
  7. forum rang 4 Pitmans 11 augustus 2022 23:32
    In the reporting quarter and year to date, the Company reached the following key milestones:

    OpGen signed its first two commercial customer contracts for the Acuitas AMR Gene Panel in June and July 2022 with a major 1,000+ bed teaching hospital in the Northeast and a renowned 400+ bed children’s hospital in the Midwest

    OpGen subsidiary Ares Genetics extended its collaboration agreement with Sandoz until 2025, to drive cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR)

    OpGen subsidiary Ares Genetics also commercially launched new sequencing and analysis services globally, which includes ARESid and ARESiss Express

    OpGen announced interim analysis results from its clinical trial for Unyvero UTI Panel and added a fourth trial site

    OpGen to date has enrolled over 1,300 patient samples in the clinical trial for Unyvero UTI Panel and is on track towards the enrollment goal of 1,500 prospective patient samples

    OpGen subsidiary Curetis and Leader Life Sciences entered into a Unyvero distribution partnership within the United Arab Emirates and Qatar for a total value of approximately $1 million in revenue during the initial three-year term

    OpGen subsidiary Curetis and Keis Group entered into a three-year exclusive Unyvero distribution partnership in Kosovo based on Keis’ successfully won tender for Unyvero products

    OpGen and Menarini expanded their distribution agreement to increase the annual minimum revenue commitment by Menarini in the next two years, in addition to the sale of around 70 installed Unyvero systems across nine European countries at residual fair market value from OpGen’s subsidiary Curetis to Menarini

    OpGen announced publication of results from a major prospective, multi center, randomized and interventional clinical study using Unyvero Hospitalized Pneumonia (HPN) Panel in The Lancet Respiratory Medicine that demonstrated Unyvero decreases the duration of inappropriate antibiotic therapy in hospitalized patients with pneumonia

    OpGen announced publication of results of Unyvero HPN Panel for detection of bacterial respiratory tract pathogens from serial specimens collected from hospitalized COVID-19 patients at Karolinska University Hospital (Sweden), confirming the ability of Unyvero in detecting potential pneumonia pathogens earlier than culture

    OpGen commenced a new At The Market (ATM) sales facility for up to approximately $10.7 million, pursuant to which the Company may sell, from time to time, in an “at the market” offering shares of its common stock. While no shares were sold under this new ATM in H1 2022, in July and August to date the Company has sold approximately 1.7 million new shares of its common stock for gross proceeds of approximately $1 million.

    OpGen requested an additional 180-day period from Nasdaq to regain compliance with the $1.00 minimum bid price rule and expects their decision by the end of August.

    In terms of fiscal 2022 guidance, OpGen expects:

    U.S. direct product sales of Unyvero and Acuitas are anticipated to contribute to growth

    Continuous increase in its European and international distribution business for Unyvero products

    Expand Ares Genetics strategic collaborations and partnerships and launch U.S. Next Generation Sequencing lab services in Q3 2022

    Overall, 2022 revenue growth of approximately 25% year over year from the products and services business globally

    Conference Call Information

    OpGen’s management will host a conference call today, August 11th at 4:30 p.m. EDT, to go over the second quarter and first half of 2022 financial results and business activities, as well as answer analyst questions.
  8. forum rang 4 Pitmans 13 augustus 2022 09:37
    cashburn H1 bijna $20mio. Met een cashvoorraad van $16.6mio wordt einde jaar dus niet gehaald.
    Maar dar is al een oplossing voor : er is alweer een nieuwe emissie van $10.7mio uitgezet, waarvan $1mio al is opgehaald door verkoop van 1.7mio stukken. In dit tempo komen er dus nog eens 18mio stukken bij.
    Maar dat is alleen maar gunstig, want zolang je verlies maakt, wordt het verlies per aandeel dus kleiner ;o)
  9. forum rang 4 Pitmans 1 september 2022 17:27
    Soort van goed nieuws. Dus daalt de koers ;o)

    Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

    OPGN -3.22%
    OpGen, Inc. Wed, August 31, 2022 at 1:30 PM

    ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has received written notification from the Listing Qualification Department of The NASDAQ Stock Market ("Nasdaq") granting OpGen’s request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").

    OpGen now has until February 27, 2023 to regain compliance with the Bid Price Rule. Nasdaq's extension notice has no immediate effect on the continued listing status of OpGen’s common stock, which remains listed on The NASDAQ Capital Market.

    If at any time until February 27, 2023, the bid price for OpGen’s common stock closes at or above $1.00 per share for a minimum of ten consecutive trading days, OpGen will regain compliance with the Bid Price Rule. OpGen will continue to monitor the bid price for its common stock and consider various available options if OpGen’s common stock does not trade at a level that is likely to regain compliance with the Bid Price Rule. There can be no assurance that OpGen will regain compliance with the Bid Price Rule or maintain compliance with any of the other Nasdaq continued listing requirements during this extended compliance period.
36 Posts
Pagina: «« 1 2 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

OpGen Meer »

Koers 0,377   Verschil 0,00 (-0,89%)
Laag 0,371   Volume 116.709
Hoog 0,394   Gem. Volume 283.318
29 sep 2022 22:00
Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

KOPEN OF VERKOPEN?

Het laatste advies leest u als IEX Premium-lid

Ontdek Premium

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links